Steven Dunn to Antigens, Neoplasm
This is a "connection" page, showing publications Steven Dunn has written about Antigens, Neoplasm.
Connection Strength
0.991
-
Fierle JK, Brioschi M, de Tiani M, Wetterwald L, Atsaves V, Abram-Saliba J, Petrova TV, Coukos G, Dunn SM. Soluble trivalent engagers redirect cytolytic T?cell activity toward tumor endothelial marker 1. Cell Rep Med. 2021 08 17; 2(8):100362.
Score: 0.699
-
D'Onofrio A, Gano L, Melo R, Mendes F, Oliveira MC, Deno?l T, Schaefer N, Viertl D, Fierle J, Coukos G, Dunn S, Prior JO, Paulo A. Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies. Eur J Pharm Biopharm. 2021 Jan; 158:233-244.
Score: 0.167
-
Li C, Wang J, Hu J, Feng Y, Hasegawa K, Peng X, Duan X, Zhao A, Mikitsh JL, Muzykantov VR, Chacko AM, Pryma DA, Dunn SM, Coukos G. Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer. Oncotarget. 2014 Aug 30; 5(16):6994-7012.
Score: 0.108
-
Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD, Dunn SM, Mahon TM, Jakobsen BK, Rosenberg SA. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol. 2008 May 01; 180(9):6116-31.
Score: 0.017